MEDIAN Technologies Announces New Awarded Projects And A New Contract For Image Interpretation And Management In Clinical Trials Totaling €5.31 Million

• Five projects awarded* including three Phase III studies sponsored by American biotech companies and by two Top 25 pharmaceutical companies.
• A contract signed for a Phase Ib/II study sponsored by an American biotech company.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

MEDIAN Technologies (Paris:ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today that it has been selected to provide imaging solutions and services for six new clinical studies in oncology. These six new projects total approximately €5.31M and include the following:

• Awarded projects:
  • A phase III study (non-small cell lung cancer - NSCLC) for a total of €1.8M
  • A phase III study (glioblastoma) for a total of €1.49M
  • A phase III study (metastatic gastric adenocarcinoma) for a total of €846,000
  • A phase Ib/II study (metastatic breast cancer) for a total of €378,000
  • A phase II study (myelofibrosis) for a total of €259,000
• Contract: a phase Ib/II study (kidney cancer) for a total of €532,000

The six studies are sponsored by major US West Coast based biotech companies that specialize in oncology and immuno-oncology and that are new MEDIAN Technologies’ clients, and by two Top 25 pharmaceutical companies, one of which is a new client for MEDIAN Technologies.

“These different projects are representative of a number of major factors supporting MEDIAN Technologies’ development in the oncology clinical trial market,” said Jerome Windsor, VP Business Development Pharma. “These factors are first the growing number of projects sponsored by biotech companies; second, MEDIAN’s increasing involvement in immuno-oncology trials, particularly clinical trials on molecules targeting PD1 receptors - a major area in research and development today- and, finally, the multiplier effect that phase III projects create in terms of business volumes.”

As of today and since January 1, 2015, MEDIAN Technologies’ order book for new awarded projects and contracts signed has grown to €9.6M compared to a figure of €9M for the entire year 2014.

*A project award is a notification announcing that the company’s solution has been selected for a specific project. This should result in a signed contract within 18 months, subject to upstream clinical results.

About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market. ISIN: FR0011049824– ticker: ALMDT The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechnologies.com

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”